Analysts at Bank of America initiated coverage on shares of Guardant Health (NASDAQ:GH) in a research report issued on Monday, October 29th, Marketbeat reports. The brokerage set a “neutral” rating and a $37.00 price target on the stock. Bank of America’s target price suggests a potential downside of 0.43% from the company’s current price.
Shares of NASDAQ:GH traded up $2.42 during trading on Monday, reaching $37.16. The stock had a trading volume of 680,737 shares, compared to its average volume of 368,374. Guardant Health has a one year low of $27.04 and a one year high of $44.25.
Guardant Health (NASDAQ:GH) last released its earnings results on Monday, November 19th. The company reported ($1.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($1.65). The company had revenue of $21.70 million for the quarter, compared to the consensus estimate of $17.44 million. The firm’s revenue was up 95.5% compared to the same quarter last year. As a group, equities research analysts forecast that Guardant Health will post -1.05 EPS for the current year.
Guardant Health Company Profile
Guardant Health, Inc, a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA.
See Also: What are Institutional Investors?
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.